We are live on ! Find out more
FCM

Farallon Capital Management Portfolio holdings

AUM $21.7B
1-Year Est. Return 79.24%
This Fund
S&P 500
This Quarter Est. Return
+33.18%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$21.7B
AUM Growth
+$2.61B
Cap. Flow
-$3.46B
Cap. Flow %
-15.95%
Top 10 Hldgs %
62.14%
Holding
194
New
19
Increased
30
Reduced
23
Closed
105

Top Buys

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$166M
2
ROIV icon
Roivant Sciences
ROIV
+$137M
3
IMVT icon
Immunovant
IMVT
+$130M
4
BBIO icon
BridgeBio Pharma
BBIO
+$96.5M
5
BIDU icon
Baidu
BIDU
+$94.1M

Top Sells

Rank Stock Value
1
MSFT icon
Microsoft
MSFT
+$498M
2
AMZN icon
Amazon
AMZN
+$398M
3
SCHW
Charles Schwab
SCHW
+$372M
4
AON icon
Aon
AON
+$365M
5
GOOG icon
Alphabet (Google) Class C
GOOG
+$286M

Sector Composition

Rank Sector Weight
1 Healthcare 54.84%
2 Miscellaneous 21.83%
3 Communication Services 8.41%
4 Technology 5.7%
5 Financials 3.99%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ANNA
76
AleAnna Inc
ANNA
$127M
$227K ﹤0.01%
78,400
– –
WELL icon
77
Welltower
WELL
$174B
$227K ﹤0.01%
1,000
-199,000
-100% -$42.1M
SLDPW icon
78
Solid Power Inc Warrant
SLDPW
$4.58M
$41.4K ﹤0.01%
405,316
– –
BGLWW
79
Blue Gold Ltd Warrant
BGLWW
$316K
$30.7K ﹤0.01%
255,800
-44,200
-15% -$9.51K
PACB icon
80
Pacific Biosciences
PACB
$404M
$23.9K ﹤0.01%
14,200
-120,800
-89% -$176K
GERN icon
81
Geron
GERN
$970M
$18.4K ﹤0.01%
14,400
-28,600
-67% -$40.3K
NVNIW
82
Nvni Group Limited Warrants
NVNIW
$17.6K ﹤0.01%
375,000
– –
CGC
83
Canopy Growth
CGC
$437M
$17.1K ﹤0.01%
18,000
-12,000
-40% -$12.7K
RANI icon
84
Rani Therapeutics
RANI
$98.4M
$15.7K ﹤0.01%
20,700
-57,300
-73% -$50.8K
BYND icon
85
Beyond Meat
BYND
$194M
$14.3K ﹤0.01%
633
– –
ADPT icon
86
Adaptive Biotechnologies
ADPT
$3.92B
– –
-11,000
Closed -$153K
AFRM icon
87
Affirm
AFRM
$25.1B
– –
-108,000
Closed -$4.95M
AIR icon
88
AAR Corp
AIR
$5.06B
– –
-46,000
Closed -$5.04M
ALKS icon
89
Alkermes
ALKS
$7.86B
– –
-20,800
Closed -$735K
ALT icon
90
Altimmune
ALT
$628M
– –
-27,600
Closed -$85K
AMKR icon
91
Amkor Technology
AMKR
$11.7B
– –
-104,000
Closed -$4.68M
APLS
92
DELISTED
Apellis Pharmaceuticals
APLS
– –
-6,000
Closed -$241K
ARDX icon
93
Ardelyx
ARDX
$958M
– –
-23,000
Closed -$138K
ARQT icon
94
Arcutis Biotherapeutics
ARQT
$2.97B
– –
-26,000
Closed -$613K
ARWR icon
95
Arrowhead Research
ARWR
$12.2B
– –
-15,800
Closed -$991K
AXSM icon
96
Axsome Therapeutics
AXSM
$10.9B
– –
-4,000
Closed -$676K
BCRX icon
97
BioCryst Pharmaceuticals
BCRX
$2.58B
– –
-24,000
Closed -$228K
BLTE
98
Belite Bio
BLTE
$6.89B
– –
-1,300
Closed -$207K
C icon
99
Citigroup
C
$232B
– –
-47,000
Closed -$5.33M
CAH icon
100
Cardinal Health
CAH
$57.8B
– –
-368,000
Closed -$77.8M
2 3
4
5 6

Similar funds

BG
Bahl & Gaynor Cincinnati, Ohio $21.7B AUM 30.58% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Farallon Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, Farallon Capital Management held 194 positions worth $21.7B, up 14% from $19.1B the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Farallon Capital Management withdrew a net $3.46B in Q2 2026, closing 105 positions and reducing 23 holdings. Its most notable exit was Charles Schwab, an estimated $372M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 55% of assets, up from 47% a quarter earlier, followed by Miscellaneous and Communication Services.

Against the trend, Farallon Capital Management opened a new position in Parabilis Medicines Inc worth $64.8M.

  • Farallon Capital Management's largest Q2 2026 buy was Parabilis Medicines Inc: 2,368,200 shares worth $64.8M.
  • Farallon Capital Management added most to Boston Scientific in Q2 2026, an estimated $166M increase.
  • Farallon Capital Management's biggest Q2 2026 reduction was Microsoft, cutting an estimated $498M.
  • Farallon Capital Management fully exited Charles Schwab in Q2 2026, selling an estimated $372M.
  • Farallon Capital Management's ten largest holdings make up 62% of its $21.7B portfolio in Q2 2026.
  • Farallon Capital Management opened 19 new positions and closed 105 in Q2 2026.
  • Farallon Capital Management's portfolio value rose 14% quarter-over-quarter to $21.7B.

Based on Farallon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.